[1]周永安,阮 勇.白蛋白结合型紫杉醇与多西紫杉醇在人表皮生长因子受体-2阳性乳腺癌患者新辅助化疗中的疗效对比研究[J].陕西医学杂志,2024,(9):1236-1239,1244.[doi:DOI:10.3969/j.issn.1000-7377.2024.09.018]
　ZHOU Yongan,RUAN Yong.Efficacy of albumin-bound paclitaxel and docetaxel in neoadjuvant chemotherapy of patients with HER2-positive breast cancer[J].,2024,(9):1236-1239,1244.[doi:DOI:10.3969/j.issn.1000-7377.2024.09.018]
点击复制

白蛋白结合型紫杉醇与多西紫杉醇在人表皮生长因子受体-2阳性乳腺癌患者新辅助化疗中的疗效对比研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2024年9期
页码:
1236-1239,1244
栏目:
药物与临床
出版日期:
2024-09-05

文章信息/Info

Title:
Efficacy of albumin-bound paclitaxel and docetaxel in neoadjuvant chemotherapy of patients with HER2-positive breast cancer
作者:
周永安1; 2; 阮 勇3
(1.锦州医科大学,辽宁 锦州 121001; 2.黄石市中心医院 湖北理工学院附属医院乳腺甲状腺外Ⅱ科,湖北 黄石 435000; 3.鄂东医养集团黄石市第二医院胃肠外科,湖北 黄石 435000)
Author(s):
ZHOU Yongan; RUAN Yong
(Jinzhou Medical University,Jinzhou 121001,China)
关键词:
乳腺癌;  白蛋白结合型紫杉醇;  曲妥珠单抗;  帕妥珠单抗;  多西紫杉醇;  人表皮生长因子受体-2;  新辅助化疗
Keywords:
Breast cancer;  Albumin-bound paclitaxel;  Trastuzumab;  Pertuzumab;  Docetaxel;  Human epidermal growth factor receptor-2;  Neoadjuvant chemotherapy
分类号:
R 737.9
DOI:
DOI:10.3969/j.issn.1000-7377.2024.09.018
文献标志码:
A
摘要:
目的:分析曲妥珠单抗+帕妥珠单抗分别联合不同类型紫杉醇应用于人表皮生长因子受体-2(HER2)阳性乳腺癌的疗效。方法:纳入90例拟行新辅助化疗的HER2阳性乳腺癌患者,根据曲妥珠单抗+帕妥珠单抗分别联合不同类型紫杉醇,将患者分为两组,44例采用多西紫杉醇方案化疗分为对照组,46例采用白蛋白结合型紫杉醇方案化疗分为观察组。以21 d为1个周期,治疗6个周期后,比较两组近期疗效、化疗前后Ki-67阳性率、基质金属蛋白酶-9(MMP-9)相对表达量、组织多肽特异性抗原(TPS)水平、生存情况、不良反应。结果:两组客观缓解率、疾病控制率比较差异无统计学意义(均P>0.05),两组总体病理完全缓解率比较差异有统计学意义(P<0.05)。治疗6个周期后,两组Ki-67阳性率、MMP-9相对表达量、TPS水平均降低,且观察组低于对照组(均P<0.05)。观察组中位生存期长于对照组(P<0.05)。两组不良反应比较差异无统计学意义(均P>0.05)。结论:相较于多西紫杉醇,白蛋白结合型紫杉醇可提高HER2阳性乳腺癌患者总体病理完全缓解率,降低Ki-67阳性率、MMP-9相对表达量和TPS水平,延长患者生存期。
Abstract:
Objective:To analyze the efficacy of trastuzumab+pertuzumab combined with different types of paclitaxel in the treatment of patients with human epidermal growth factor receptor-2(HER2)-positive breast cancer.Methods:The 90 patients with HER2-positive breast cancer included in this study were scheduled to receive neoadjuvant chemotherapy.Patients were divided into two groups according to trastuzumab+pertuzumab combined with different types of paclitaxel,and 44 cases with docetaxel chemotherapy regimen were enrolled as control group,and the remaining 46 cases receiving albumin-bound paclitaxel chemotherapy regimen were included in observation group.Both groups took 21 days as one cycle of treatment.The short-term efficacy after 6 cycles of treatment,the positive rate of Ki-67,the relative expression of MMP-9 and the level of TPS before and after chemotherapy,survival status and adverse reactions were compared between groups.Results:There were no statistical differences in objective response rate and disease control rate between both groups(all P>0.05).The overall pathological complete response rate of the two groups was statistically significant(P<0.05).After 6 cycles of treatment,the positive rate of Ki-67,relative expression level of MMP-9 and TPS level in the two groups were decreased,and the above indicators were lower in observation group than those in control group(all P<0.05).The median survival time in observation group was longer compared to control group(P<0.05).The adverse reactions between the two groups were not statistically different(all P>0.05).Conclusion:Compared with docetaxel,albumin-bound paclitaxel can better improve the total pathological complete response rate of patients with HER2-positive breast cancer,reduce the positive rate of Ki-67,relative expression of MMP-9 and level of TPS,and prolong the survival time of patients.

参考文献/References:

[1] 邵志博,杨犇龙,吴炅.2022年中国乳腺癌重要临床试验成果及最新进展[J].中国癌症杂志,2023,33(2):103-109.
[2] RUBIN E,SHAN K S,DALAL S,et al.Molecular targeting of the human epidermal growth factor receptor-2(HER2)genes across various cancers[J].Int J Mol Sci,2024,25(2):1064.
[3] YOSHIMOTO S,KATO D,KAMOTO S,et al.Overexpression of human epidermal growth factor receptor 2 in canine primary lung cancer[J].J Vet Med Sci,2020,82(6):804-808.
[4] 朱平,吕泓,柏乾明,等.HER2阳性乳腺癌新辅助治疗疗效临床病理学分析[J].中华病理学杂志,2023,52(9):907-911.
[5] 王晓敏,彭璐珊,王潇潇,等.不同HER-2表达水平乳腺癌患者新辅助化疗疗效与生存分析[J].中国普通外科杂志,2023,32(5):739-751.
[6] 李昊城,卢志扬,奉建芳,等.难溶性多西紫杉醇的溶解微针制备及体外评价[J].中国医院药学杂志,2023,43(3):272-277.
[7] ROVIELLO G,CONTER F U,MINI E,et al.Nanoparticle albumin-bound paclitaxel:A big nano for the treatment of gastric cancer[J].Cancer Chemother Pharmacol,2019,84(4):669-677.
[8] 国家卫生健康委员会医政医管局.乳腺癌诊疗指南(2022年版)[J].中国综合临床,2024,40(1):1-30.
[9] LALCHANDANI U R,SAHAI V,HERSBERGER K,et al.A radiologist's guide to response evaluation criteria in solid tumors[J].Curr Probl Diagn Radiol,2019,48(6):576-585.
[10] YAU C,OSDOIT M,SHAD S,et al.Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer:A multicentre pooled analysis of 5161 patients[J].Lancet Oncol,2022,23(1):149-160.
[11] 皋文君,刘砚燕,袁长蓉.国际肿瘤化疗药物不良反应评价系统——通用不良反应术语标准4.0版[J].肿瘤,2012,32(2):142-144.
[12] SUNG H,FERLAY J,SIEGEL R L,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
[13] 杨红,王洲,任永凤,等.超声特征与临床因素对HER2+浸润性乳腺癌的预测价值[J].陕西医学杂志,2023,52(8):1051-1054.
[14] 游紫萱,郑晓筱.逍遥蒌贝散对乳腺癌根治术患者外周血T淋巴细胞及引流液炎症指标的影响[J].陕西中医,2021,42(2):183-186.
[15] 张慧峰,李茉,许淑娣,等.拉帕替尼治疗HER2阳性局部晚期乳腺癌临床疗效研究[J].陕西医学杂志,2023,52(5):596-599.
[16] 魏松之,魏淑琴,李铂.新辅助用药帕妥珠单抗联合曲妥珠单抗在局部晚期、炎症性或早期her2阳性老年乳腺癌患者中有效性及安全性[J].中国老年学杂志,2023,43(1):44-47.
[17] AMIN S,POLLEY S,DEFRATES S,et al.National comprehensive cancer network investigational drug service consensus recommendations[J].Am J Health Syst Pharm,2022,79(6):486-491.
[18] 唐耀,廖冬颖,宋金鸣,等.紫杉醇类化疗药物导致骨髓抑制的中医药防治进展[J].陕西中医,2021,42(12):1822-1824.
[19] 中国医师协会肿瘤医师分会乳腺癌学组,中国抗癌协会国际医疗交流分会.白蛋白结合型紫杉醇治疗乳腺癌的中国专家共识[J].中华肿瘤杂志,2023,45(3):203-211.
[20] 岳瑞雪,胡崇珠,郝鑫,等.曲妥珠单抗和帕妥珠单抗联合不同化疗方案新辅助治疗HER-2阳性乳腺癌真实世界疗效及安全性观察[J].中国肿瘤临床,2023,50(5):248-254.
[21] 王福倩,王帅,毛锡金,等.机器学习基于乳腺癌瘤内、瘤周多模态MRI影像组学特征预测Ki-67表达的研究[J].实用放射学杂志,2023,39(10):1606-1610.
[22] 邓姣,陈宽冰.Ki-67、Her-2及CD147在老年女性乳腺癌中的表达及意义[J].中国老年学杂志,2023,43(5):1054-1057.
[23] 姚立勇,陈敏,梁豪,等.七氟醚对乳腺癌细胞NF-κB活性及MMP-2、MMP-9表达的影响[J].中国妇幼保健,2019,34(1):177-181.
[24] 胡耀峰,郭晶,任栋梁,等.赫赛汀AC-TH化疗方案治疗Her-2阳性乳腺癌对血清Her-2-ECD、TPS及远期疗效的影响[J].中华实验外科杂志,2023,40(1):77.
[25] 孙宁,范晓娜,李恒震,等.白蛋白结合型紫杉醇三周疗和剂量密集疗治疗晚期胰腺癌的疗效观察[J].现代肿瘤医学,2023,31(20):3805-3811.

相似文献/References:

[1]乔亚舜,吴瑛琦.乳腔镜腋窝淋巴结清扫术治疗早期乳腺癌临床研究[J].陕西医学杂志,2019,(4):473.
　QIAO Yashun,WU Yingqi..Clinical study of mammoscopic axillary lymph node dissection for early breast cancer patients[J].,2019,(9):473.
[2]谭兴利,陆伟辉,汤学文,等.乳腺癌患者超声检查中PSV、RI值与术后组织中MMP11、VEGF表达的相关性探讨[J].陕西医学杂志,2019,(5):617.
[3]韩丕华,宋张骏△,杨晓民,等.乳腺超声造影联合细针穿刺定位活检在判定乳腺癌新辅助化疗后腋窝淋巴结性质中的临床研究*[J].陕西医学杂志,2019,(7):842.
　HAN Pihua,SONG Zhangjun,YANG Xiaomin,et al.Application of breast contrast-enhanced ultrasonography combined with fine needle aspiration biopsy in determining the axillary lymph node properties after neoadjuvant chemotherapy for breast cancer[J].,2019,(9):842.
[4]蒋 敢,王 军,王会东△.舒芬太尼联合罗哌卡因肋间神经阻滞对乳腺癌患者术后镇痛、免疫功能及应激反应的影响*[J].陕西医学杂志,2019,(8):1077.
　JIANG Gan,WANG Jun,WANG Huidong..Effect of sufentanil plus ropivacaine intercostal nerve block on postoperative analgesia, immunity and stress response in patients with breast cancer[J].,2019,(9):1077.
[5]王群拴,黎小花△.核磁共振结合血清肿瘤标志物及细胞因子检测在〖JZ〗乳腺癌诊断中的应用价值研究*[J].陕西医学杂志,2019,(10):1295.
[6]韩丕华,袁 权△.乳腺癌患者白细胞介素-22表达水平对新辅助化疗后病理学完全缓解的预测价值*[J].陕西医学杂志,2020,49(7):889.[doi:DOI:10.3969/j.issn.10007377.2020.07.033]
　HAN Pihua,YUAN Quan..Predictive value of IL-22 expression level in breast cancer patients for pathological complete remission after neoadjuvant chemotherapy[J].,2020,49(9):889.[doi:DOI:10.3969/j.issn.10007377.2020.07.033]
[7]韩金怡,苏志勇.21基因检测对早期Luminal A型乳腺癌治疗指导作用研究[J].陕西医学杂志,2021,50(9):1081.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.010]
　HAN Jinyi,SU Zhiyong.Guiding role of 21-gene detection in treatment of early Luminal type A breast cancer[J].,2021,50(9):1081.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.010]
[8]白玲娇,陈小军,王 婷.乳腺癌超声弹性成像评分与免疫组化指标表达水平相关性分析[J].陕西医学杂志,2021,50(10):1239.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.015]
[9]郑 超,苏 娟,盛杰鑫,等.乳腺癌患者病灶血流时间-信号强度曲线类型、表观弥散系数与化疗疗效相关性分析[J].陕西医学杂志,2021,50(12):1521.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.013]
　ZHENG Chao,SU Juan,SHENG Jiexin,et al.Correlation between focal blood flow time-signal intensity curve type,apparent diffusion coefficient and chemotherapy efficacy in breast cancer patients[J].,2021,50(9):1521.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.013]
[10]李福平,王 茂,邱春丽,等.莱菔硫烷联合维生素D对乳腺癌细胞增殖及凋亡的影响[J].陕西医学杂志,2022,51(8):916.[doi:DOI:10.3969/j.issn.1000-7377.2022.08.003]
　LI Fuping,WANG Mao,QIU Chunli,et al.Effect of sulforaphane combined with vitamin D on proliferation and apoptosis of breast cancer cells[J].,2022,51(9):916.[doi:DOI:10.3969/j.issn.1000-7377.2022.08.003]

备注/Memo

备注/Memo:
基金项目:湖北省医学科研课题(HBJG-200059); 湖北省黄石市中心医院科研项目(ZX2023Q04)
更新日期/Last Update: 2024-09-04